Malignant peritoneal mesothelioma

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Marjorie G. Zauderer, MD, MS, FACP
Memorial Sloan Kettering Cancer Center
New York, NY, USA
1 regimens on this page
1 variants on this page


Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.



Advanced or metastatic disease, subsequent lines of therapy

Atezolizumab & Bevacizumab


Study Dates of enrollment Evidence
Raghav et al. 2021 (MDACC 2016-0861) 2017-2019 Phase 2


Targeted therapy

21-day cycles


  1. MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT03074513